Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership comes as Matchpoint advances its pipeline of innovative oral small molecule drugs targeting autoimmune and inflammatory diseases, following a recent $150 million Series B funding round. This strategic hire aims to accelerate the clinical development of Matchpoint’s first-in-class precision covalent medicines.

As of Oct 14, 2026 18:11 WIB, CRISPR Therapeutics (CRSP), where John O’Malley previously worked, trades at USD 50.50 with a 1-day gain of 0.80% on Pluang. Sanofi (SNY), another of his former employers, is priced at USD 39.67, up 1.41% for the day. Pluang investors show full buying interest in CRSP and a majority buying activity in SNY, reflecting ongoing attention to companies linked to Matchpoint’s new chief medical officer.